Pesticides & Agrochemicals · Founded 1996 · www.insecticidesindia.com · BSE 532851 · NSE INSECTCID · ISIN INE070I01018
No Notes Added Yet
Business
Insecticides (India) Ltd. (IIL) is a prominent Indian manufacturer and marketer of agrochemical products. The company develops, formulates, and distributes a wide range of crop protection products including insecticides, herbicides, fungicides, and plant growth regulators (PGRs). Its core business model involves catering to the agricultural needs of Indian farmers by providing solutions to protect crops from pests and diseases, thereby improving yield and quality. IIL makes money by selling these agrochemical formulations and technical-grade active ingredients through an extensive distribution network across India.
Revenue Mix
The company primarily operates in two key segments:
Formulations: This involves manufacturing and selling finished agrochemical products by mixing various active ingredients with other carriers and adjuvants. This segment typically contributes the majority of its revenue due to direct sales to farmers.
Technical: This segment involves manufacturing active ingredients (technical grade) that are used in the formulation of pesticides. IIL manufactures some key technicals in-house, enabling backward integration, reducing reliance on external suppliers, and offering cost advantages. Specific percentage contributions are not consistently disclosed publicly but formulations are generally the larger revenue driver.
Industry
The Indian Pesticides & Agrochemicals industry is highly competitive, characterized by the presence of both domestic players and multinational corporations. The industry's performance is significantly influenced by monsoon patterns, crop acreage, government policies, and farmer awareness. Insecticides (India) Ltd. is positioned as one of the leading domestic agrochemical companies in India, with a strong focus on generic products and a growing emphasis on proprietary molecules and formulations. It boasts a wide distribution network, reaching farmers across various states. The company differentiates itself through its R&D capabilities, extensive product portfolio, and manufacturing expertise in both technicals and formulations.
MOAT
Extensive Distribution Network: A deep and wide distribution reach across rural and semi-urban India is crucial for agrochemical companies. IIL has established a strong network, providing access to a large farmer base.
R&D Capabilities & Product Portfolio: Ability to synthesize technicals and develop new formulations, including proprietary products, allows for product differentiation and better margins compared to solely generic players. A broad portfolio caters to diverse crop and pest requirements.
Backward Integration: Manufacturing key technicals in-house reduces import dependence, provides cost control, and ensures supply chain stability, especially for its generic products.
Brand Recognition: Specific product brands have built recognition and trust among Indian farmers over time.
Growth Drivers
Increasing Food Demand: India's growing population and evolving dietary habits drive the need for higher agricultural output, increasing demand for crop protection.
Awareness & Adoption of Agrochemicals: Growing awareness among farmers about yield losses due to pests and diseases, coupled with education on proper agrochemical usage, leads to increased adoption.
Government Support & Policies: Initiatives by the Indian government to boost agricultural productivity and farmer income (e.g., MSP hikes, irrigation projects) can indirectly drive demand.
New Product Launches: Introduction of new generic molecules, specialized formulations, and proprietary products can capture market share and drive revenue growth.
Export Opportunities: Leveraging its technical manufacturing capabilities to export active ingredients and formulations to international markets.
Risks
Monsoon Dependence: The Indian agricultural sector is heavily reliant on the monsoon. Erratic or deficient rainfall can severely impact crop cycles and farmer purchasing power, affecting demand for agrochemicals.
Regulatory Changes: The agrochemical industry is subject to stringent environmental and health regulations. Bans on specific pesticides or changes in registration processes can impact product portfolios and profitability.
Input Cost Volatility: Fluctuations in crude oil prices (a key raw material for many agrochemicals) and other chemical inputs can impact manufacturing costs and margins.
Intense Competition: The presence of numerous domestic and multinational players leads to pricing pressure and market share battles.
Counterfeit Products: The prevalence of spurious and low-quality products in the market poses a threat to legitimate players' sales and brand reputation.
Pest Resistance: Pests and diseases can develop resistance to existing agrochemicals, necessitating continuous R&D and product innovation, which involves significant investment.
Management & Ownership
Insecticides (India) Ltd. is a promoter-driven company, with the Agarwal family being the primary promoters. Mr. Rajesh Aggarwal (Managing Director) plays a key role in the company's strategic direction and operations, having significant experience in the agrochemical sector. The ownership structure typically includes a substantial promoter holding, alongside investments from institutional investors (domestic and foreign) and public shareholders. The management team has experience in navigating the complexities of the Indian agricultural market and executing growth strategies.
Outlook
IIL operates in an essential sector for the Indian economy. The long-term outlook for the Indian agrochemical industry remains positive due to the fundamental need for food security and increasing agricultural intensification.
Bull Case: Favorable monsoons, successful launch of new high-margin products (both generic and proprietary), effective expansion into new geographies or crop segments, and stable raw material prices could drive strong revenue and profit growth. Continued government support for agriculture and growing farmer awareness would further bolster demand.
Bear Case: Adverse monsoon conditions leading to poor harvests, intense pricing pressure from competitors, sudden regulatory bans on key products, or significant volatility in raw material costs could impact profitability and growth. The company also faces the challenge of continually investing in R&D to stay ahead of pest resistance and competitive offerings. Overall, IIL is positioned to benefit from structural growth in Indian agriculture, but its performance remains susceptible to inherent agricultural and regulatory uncertainties.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 696 | 358 | 273 | 657 | 627 | 358 | 359 | 691 | 638 | 385 |
| Other Income | -0 | 1 | 5 | 2 | 2 | 0 | 3 | 4 | 3 | 1 |
| Total Income | 696 | 359 | 277 | 659 | 628 | 358 | 362 | 695 | 640 | 386 |
| Total Expenditure | 614 | 332 | 264 | 585 | 537 | 327 | 330 | 607 | 548 | 358 |
| Operating Profit | 82 | 27 | 13 | 75 | 91 | 31 | 31 | 88 | 92 | 28 |
| Interest | 3 | 3 | 2 | 2 | 2 | 1 | 2 | 4 | 4 | 5 |
| Depreciation | 7 | 7 | 8 | 7 | 7 | 8 | 7 | 7 | 9 | 9 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 72 | 17 | 4 | 66 | 82 | 22 | 22 | 77 | 79 | 14 |
| Provision for Tax | 19 | 5 | -4 | 17 | 21 | 5 | 8 | 19 | 20 | 4 |
| Profit After Tax | 53 | 12 | 8 | 49 | 61 | 17 | 14 | 58 | 59 | 10 |
| Adjustments | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 53 | 12 | 8 | 49 | 61 | 17 | 14 | 58 | 59 | 10 |
| Adjusted Earnings Per Share | 18 | 4.1 | 2.5 | 16.7 | 20.7 | 6 | 4.8 | 20 | 20.3 | 3.6 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 965 | 988 | 994 | 1073 | 1194 | 1363 | 1420 | 1504 | 1801 | 1966 | 2000 | 2073 |
| Other Income | 1 | 1 | 7 | 3 | 1 | 3 | 8 | 4 | 1 | 9 | 7 | 11 |
| Total Income | 966 | 989 | 1001 | 1076 | 1194 | 1366 | 1428 | 1508 | 1803 | 1976 | 2007 | 2083 |
| Total Expenditure | 854 | 896 | 883 | 925 | 1006 | 1207 | 1268 | 1334 | 1679 | 1804 | 1779 | 1843 |
| Operating Profit | 112 | 93 | 118 | 151 | 188 | 158 | 160 | 174 | 123 | 172 | 228 | 239 |
| Interest | 33 | 26 | 20 | 16 | 15 | 24 | 7 | 7 | 13 | 11 | 7 | 15 |
| Depreciation | 15 | 16 | 16 | 17 | 20 | 24 | 25 | 26 | 26 | 29 | 29 | 32 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | -10 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 64 | 50 | 82 | 118 | 153 | 110 | 120 | 141 | 84 | 132 | 193 | 192 |
| Provision for Tax | 9 | 11 | 23 | 34 | 31 | 24 | 26 | 34 | 21 | 30 | 51 | 51 |
| Profit After Tax | 55 | 40 | 59 | 84 | 122 | 86 | 94 | 107 | 63 | 102 | 142 | 141 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 55 | 40 | 60 | 84 | 123 | 87 | 94 | 107 | 63 | 102 | 142 | 141 |
| Adjusted Earnings Per Share | 19.2 | 12.8 | 19.3 | 27.2 | 39.6 | 28 | 30.3 | 36.3 | 21.4 | 34.5 | 48.8 | 48.7 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 2% | 10% | 8% | 8% |
| Operating Profit CAGR | 33% | 9% | 8% | 7% |
| PAT CAGR | 39% | 10% | 11% | 10% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -6% | 19% | 16% | 10% |
| ROE Average | 14% | 10% | 11% | 14% |
| ROCE Average | 18% | 13% | 14% | 16% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 291 | 409 | 464 | 548 | 662 | 732 | 820 | 870 | 918 | 1012 | 1085 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 54 | 28 | 15 | 8 | 1 | 2 | 2 | 2 | 2 | 29 | 23 |
| Other Non-Current Liabilities | 20 | 24 | 26 | 45 | 52 | 44 | 50 | 53 | 38 | 47 | 13 |
| Total Current Liabilities | 556 | 475 | 489 | 425 | 674 | 539 | 585 | 508 | 760 | 664 | 833 |
| Total Liabilities | 920 | 936 | 995 | 1026 | 1388 | 1317 | 1457 | 1432 | 1718 | 1752 | 1954 |
| Fixed Assets | 205 | 198 | 185 | 232 | 240 | 239 | 239 | 253 | 262 | 283 | 279 |
| Other Non-Current Assets | 52 | 62 | 96 | 75 | 86 | 100 | 133 | 176 | 224 | 217 | 194 |
| Total Current Assets | 662 | 675 | 715 | 719 | 1062 | 978 | 1086 | 1003 | 1232 | 1252 | 1481 |
| Total Assets | 920 | 936 | 995 | 1026 | 1388 | 1317 | 1457 | 1432 | 1718 | 1752 | 1954 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 12 | 9 | 7 | 7 | 20 | 9 | 68 | 6 | 36 | 19 | 61 |
| Cash Flow from Operating Activities | -6 | 86 | 4 | 182 | -133 | 242 | 155 | 135 | -11 | 187 | 93 |
| Cash Flow from Investing Activities | -34 | -19 | -14 | -26 | -49 | -24 | -113 | 9 | -86 | -46 | -38 |
| Cash Flow from Financing Activities | 36 | -64 | 9 | -143 | 172 | -159 | -104 | -115 | 80 | -98 | -61 |
| Net Cash Inflow / Outflow | -4 | 4 | -0 | 13 | -11 | 59 | -61 | 30 | -17 | 42 | -5 |
| Closing Cash & Cash Equivalent | 9 | 12 | 7 | 20 | 9 | 68 | 6 | 36 | 19 | 61 | 56 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 19.22 | 12.77 | 19.26 | 27.19 | 39.62 | 28.03 | 30.29 | 36.3 | 21.36 | 34.49 | 48.81 |
| CEPS(Rs) | 24.34 | 18.08 | 24.32 | 32.59 | 45.83 | 35.52 | 38.25 | 45.2 | 30.18 | 44.37 | 58.83 |
| DPS(Rs) | 2.5 | 2 | 2 | 2 | 2 | 6 | 2 | 3 | 3 | 3 | 2 |
| Book NAV/Share(Rs) | 101.12 | 131.38 | 149.83 | 176.71 | 213.54 | 236.03 | 264.62 | 293.81 | 310.26 | 341.82 | 372.74 |
| Core EBITDA Margin(%) | 10.75 | 8.78 | 10.35 | 12.13 | 14.31 | 10.31 | 9.6 | 10.28 | 6.14 | 7.39 | 9.91 |
| EBIT Margin(%) | 9.4 | 7.28 | 9.5 | 10.99 | 12.86 | 8.89 | 7.95 | 8.96 | 4.9 | 6.5 | 8.95 |
| Pre Tax Margin(%) | 6.19 | 4.8 | 7.62 | 9.69 | 11.7 | 7.31 | 7.53 | 8.56 | 4.22 | 6.01 | 8.64 |
| PAT Margin (%) | 5.31 | 3.78 | 5.52 | 6.89 | 9.36 | 5.69 | 5.92 | 6.51 | 3.18 | 4.65 | 6.37 |
| Cash Profit Margin (%) | 6.73 | 5.35 | 7.01 | 8.29 | 10.87 | 7.29 | 7.47 | 8.1 | 4.5 | 5.98 | 7.67 |
| ROA(%) | 9.78 | 4.26 | 6.15 | 8.31 | 10.14 | 6.36 | 6.77 | 7.44 | 4.01 | 5.88 | 7.66 |
| ROE(%) | 28.42 | 11.38 | 13.63 | 16.59 | 20.24 | 12.35 | 12.1 | 12.71 | 7.07 | 10.58 | 13.55 |
| ROCE(%) | 26.91 | 12.46 | 15.55 | 19.66 | 20.65 | 14.24 | 13.74 | 16.13 | 9.75 | 13.15 | 17.52 |
| Receivable days | 35.35 | 65.22 | 71.11 | 66.83 | 66.86 | 68.11 | 66.07 | 60.07 | 53.79 | 49.29 | 55.78 |
| Inventory Days | 86.22 | 129.21 | 131.65 | 124.71 | 155.24 | 147.84 | 135.75 | 142.71 | 137.14 | 138.76 | 138.53 |
| Payable days | 79.6 | 126.29 | 111.63 | 116.21 | 131.55 | 102.55 | 114.01 | 124.25 | 110.52 | 118.58 | 140.28 |
| PER(x) | 15.98 | 16.27 | 18.39 | 16.88 | 11.1 | 7.45 | 10.43 | 11.27 | 21.88 | 14.17 | 12.13 |
| Price/Book(x) | 3.04 | 1.58 | 2.36 | 2.6 | 2.06 | 0.88 | 1.19 | 1.39 | 1.51 | 1.43 | 1.59 |
| Dividend Yield(%) | 0.36 | 0.64 | 0.38 | 0.29 | 0.3 | 1.92 | 0.42 | 0.49 | 0.64 | 0.61 | 0.34 |
| EV/Net Sales(x) | 1.23 | 0.85 | 1.33 | 1.41 | 1.39 | 0.56 | 0.7 | 0.81 | 0.85 | 0.75 | 0.88 |
| EV/Core EBITDA(x) | 10.65 | 9.04 | 11.21 | 10.04 | 8.83 | 4.8 | 6.2 | 7.04 | 12.36 | 8.55 | 7.73 |
| Net Sales Growth(%) | 266.02 | 2.39 | 0.6 | 7.95 | 11.21 | 14.22 | 4.18 | 5.9 | 19.77 | 9.16 | 1.71 |
| EBIT Growth(%) | 257.38 | -21.4 | 33.97 | 31.13 | 25.53 | -20.14 | -6.1 | 17.32 | -34.27 | 46.77 | 39.82 |
| PAT Growth(%) | 162.21 | -27.82 | 50.06 | 41.37 | 45.77 | -29.71 | 9.14 | 14.4 | -41.16 | 61.48 | 39.13 |
| EPS Growth(%) | 162.2 | -33.56 | 50.82 | 41.19 | 45.7 | -29.23 | 8.04 | 19.83 | -41.16 | 61.48 | 41.52 |
| Debt/Equity(x) | 1.11 | 0.51 | 0.51 | 0.21 | 0.46 | 0.26 | 0.12 | 0.06 | 0.17 | 0.08 | 0.09 |
| Current Ratio(x) | 1.19 | 1.42 | 1.46 | 1.69 | 1.58 | 1.81 | 1.86 | 1.97 | 1.62 | 1.89 | 1.78 |
| Quick Ratio(x) | 0.49 | 0.68 | 0.59 | 0.73 | 0.53 | 0.85 | 0.73 | 0.73 | 0.49 | 0.67 | 0.71 |
| Interest Cover(x) | 2.93 | 2.94 | 5.05 | 8.42 | 11.05 | 5.62 | 18.97 | 22.31 | 7.23 | 13.11 | 29.08 |
| Total Debt/Mcap(x) | 0.37 | 0.32 | 0.22 | 0.08 | 0.22 | 0.29 | 0.1 | 0.04 | 0.12 | 0.06 | 0.06 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.16 | 72.16 | 72.16 | 72.16 | 72.3 | 72.3 | 72.3 | 72.3 | 72.3 | 72.3 |
| FII | 4.42 | 4.32 | 4.36 | 5.43 | 5.13 | 4.49 | 4.66 | 4.51 | 4.46 | 4.5 |
| DII | 9.12 | 9.14 | 9.07 | 9.06 | 9.22 | 9.58 | 9.7 | 9.48 | 9.38 | 9.25 |
| Public | 14.31 | 14.39 | 14.41 | 13.36 | 13.35 | 13.63 | 13.34 | 13.71 | 13.87 | 13.96 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.14 | 2.14 | 2.14 | 2.14 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
| FII | 0.13 | 0.13 | 0.13 | 0.16 | 0.15 | 0.13 | 0.14 | 0.13 | 0.13 | 0.13 |
| DII | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.27 | 0.27 |
| Public | 0.42 | 0.43 | 0.43 | 0.4 | 0.39 | 0.4 | 0.39 | 0.4 | 0.4 | 0.41 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.96 | 2.96 | 2.96 | 2.96 | 2.91 | 2.91 | 2.91 | 2.91 | 2.91 | 2.91 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +2% | +10% | +8% | +8% |
| Operating Profit CAGR | +33% | +9% | +8% | +7% |
| PAT CAGR | +39% | +10% | +11% | +10% |
| Share Price CAGR | -6% | +19% | +16% | +10% |
| ROE Average | +14% | +10% | +11% | +14% |
| ROCE Average | +18% | +13% | +14% | +16% |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 72.16 | 72.16 | 72.16 | 72.16 | 72.3 | 72.3 | 72.3 | 72.3 | 72.3 | 72.3 |
| FII | 4.42 | 4.32 | 4.36 | 5.43 | 5.13 | 4.49 | 4.66 | 4.51 | 4.46 | 4.5 |
| DII | 9.12 | 9.14 | 9.07 | 9.06 | 9.22 | 9.58 | 9.7 | 9.48 | 9.38 | 9.25 |
| Public | 27.84 | 27.84 | 27.84 | 27.84 | 27.7 | 27.7 | 27.7 | 27.7 | 27.7 | 27.7 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 2.14 | 2.14 | 2.14 | 2.14 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 | 2.1 |
| FII | 0.13 | 0.13 | 0.13 | 0.16 | 0.15 | 0.13 | 0.14 | 0.13 | 0.13 | 0.13 |
| DII | 0.27 | 0.27 | 0.27 | 0.27 | 0.27 | 0.28 | 0.28 | 0.28 | 0.27 | 0.27 |
| Public | 0.82 | 0.82 | 0.82 | 0.82 | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 | 0.81 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2.96 | 2.96 | 2.96 | 2.96 | 2.91 | 2.91 | 2.91 | 2.91 | 2.91 | 2.91 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.